MDACC Study No:ACOSOGZ4051 ( NCT No: NCT00757172)
Title:A Phase II Study of Neoadjuvant Therapy with Cisplatin, Docetaxel, Panitumumab Plus Radiation Therapy Followed by Surgery in Patients with Locally Advanced Adenocarcinoma of the Distal Esophagus
Principal Investigator:Wayne L. Hofstetter
Treatment Agent:Cisplatin; Panitumumab; Radiation; Taxotere
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if using panitumumab in
combination with chemotherapy (cisplatin and docetaxel) and radiation before
surgery can help to control cancer of the esophagus. The safety of this
treatment combination will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Esophagus; Gastrointestine
Phase of Study:Phase II
Treatment Agents:Cisplatin
Treatment Location:Both at MDACC & Community Programs (CCOP/Network)
Estimated Length of Stay in Houston:Chemotherapy and radiation therapy will be given on an outpatient basis.
Hospitalization will be related to surgery, expected stay is 10 - 12 days
Supported By:ACOSOG
Return Visit:Every 2 weeks for 4 weeks of the study, Daily (Monday through Friday) during
weeks 5 through 9 of the study (28 days), for surgery 6 - 9 weeks after
treatment ends, 30 days post-op, every 3 months for the next 2 years, every 6
months for one year
Home Care:None

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Wayne L. Hofstetter
Dept:Thoracic & Cardiovascular
For Clinical Trial Enrollment:713-563-9152
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults